• About us
• Contact

Advertisement

Organisation › Details

Uniqure N.V. (Nasdaq: QURE)

uniQure is a world leader in the development of human gene based therapies. uniQure product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows uniQure to pursue its strategy of focusing on this sector of the industry. uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two of the leading life sciences venture capital firms in the Netherlands. *

 

	Start	2014-04-09 renamed before
	Group	Uniqure (Group)
	Predecessor	Uniqure B.V.
	Industry	gene therapy
	Industry 2	Glybera®
	Person	Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)
	Person 2	Astley-Sparke, Philip (Forbion 201209– Venture Partner before Amgen + BioVex CEO since 2005 + JP Morgan)
	Region	Amsterdam
	Country	Netherlands
	Street	61 Meibergdreef
	City	1105 BA Amsterdam
	Tel	+31-20-566-7394
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	7,281,000 (revenues, total, consolidated (2019) 2019-12-31)
	Profit	-124,201,000 (2019-12-31)
	Cash	377,793,000 (2019-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Uniqure (Group)

• [1] Uniqure N.V.. (5/15/23). "Press Release: Uniqure Announces Sale of Royalty Interest in Hemgenix for up to $400 Million". Lexington, MA & Amsterdam....
• [2] Uniqure N.V.. (1/31/23). "Press Release: uniQure and Apic Bio Enter into Global Licensing Agreement for APB-102, a Clinical Stage Gene Therapy for Patients with ALS Caused by Mutations in SOD1". Lexington, MA, Amsterdam & Cambridge, MA....
• [3] Uniqure N.V.. (11/22/22). "Press Release: Uniqure Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B". Research Triangle Park, NC....
• [4] Uniqure N.V.. (12/9/21). "Press Release: Uniqure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B". Lexington, MA, Amsterdam & King of Prussia, PA....
• [5] Uniqure N.V.. (6/22/21). "Press Release: Uniqure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)". Lexington, MA, Amsterdam & Paris....
• [6] Uniqure N.V.. (12/21/20). "Press Release: uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program". Lexington, MA & Amsterdam....
• [7] Uniqure N.V.. (6/24/20). "Press Release: Uniqure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy". Lexington, MA & Amsterdam....
• [8] Uniqure N.V.. (6/17/20). "Press Release: Uniqure Announces the Appointment of Leonard E. Post, Ph.D. to Its Board of Directors". Lexington, MA & Amsterdam....
• [9] Uniqure N.V.. (3/2/20). "Press Release: Uniqure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters". Lexington, MA & Amsterdam....
• [10] Uniqure N.V.. (3/2/20). "Press Release: Uniqure Announces 2019 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.